Evidence map›Paper›PMID 35603904›Full record

ArticleInternational journal of cancer2022

Different human papillomavirus types share early natural history transitions in immunocompetent women.

Sally N Adebamowo, Brian Befano, Li C Cheung, Ana Cecilia Rodriguez, Maria Demarco, Greg Rydzak, Xiaojian Chen, Carolina Porras, Rolando Herrero, Jane J Kim and 5 more

Open access · greenAbstract read
In one paragraph

Article in International journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Sally N AdebamowoDepartment of Epidemiology and Public Health, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-4713-2433
Brian BefanoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.ORCID 0000-0003-3614-210X
Li C CheungDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
Ana Cecilia RodriguezDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
Maria DemarcoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
Greg RydzakInformation Management Services Inc, Information Management, Calverton, New York, USA.
Xiaojian ChenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
Carolina PorrasAgencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA, San José, Costa Rica.
Rolando HerreroAgencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA, San José, Costa Rica.
Jane J KimCenter for Health Decision Science, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Philip E CastleDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.ORCID 0000-0003-1251-0836
Aimée R KreimerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
Mark SchiffmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
Nicole G CamposDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.ORCID 0000-0002-0840-4339
National Cancer Institute · USInformation Management Services · USInstituto Costarricense de Investigación y Enseñanza en Nutrición y Salud · CRManagement Sciences for Health · USUniversity of Maryland, Baltimore · US

Funding

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI FEYRUZ VIRGILIA RASSOOL · 2008 to 2026
$51.0M
Developing Data-Driven Cancer ResearchersT32CA009168 · NCI · UNIVERSITY OF WASHINGTON · PI STEPHEN M SCHWARTZ, MICHAEL Chiao-An WU · 1985 to 2026
$10.1M
African Collaborative Center for Microbiome and Genomics Research (ACCME)U54HG006947 · NHGRI · INSTITUTE OF HUMAN VIROLOGY · PI ADEBAMOWO, CLEMENT ADEBAYO · 2013 to 2018
$5.7M
Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry - Study SitesU01HG011717 · NHGRI · UNIVERSITY OF MARYLAND BALTIMORE · PI ADEBAMOWO, SALLY NNEOMA, TAYO, BAMIDELE OLUSEGUN · 2021 to 2025
$4.6M
RANDOMIZED TRIAL ON THE CLINICAL MANAGEMENT OF ASCUS ANDN01CN055155 · CN · UNIVERSITY OF WASHINGTON · PI KIVIAT, NANCY B. · 1995 to 2000
$559k
CLINICAL MANAGEMENT OF ASCUS/LSIL OF THE UTERINE CERVIXN01CN055153 · CN · WESTAT, INC. · PI ROSENTHAL, JEANNE D · 1995 to 2000
$244k
RANDOMIZED TRIAL ON THE CLINICAL MANAGEMENT OFN01CN055158 · CN · MEDICAL COLLEGE OF GEORGIA (MCG) · PI FERRIS, DARRON D · 1995 to 1999
–
RANDOMIZED TRIAL ON THE CLINICAL MANAGEMENT OF ASCUS ANDN01CN055154 · CN · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI PARTRIDGE, EDWARD E · 1995 to 2000
–
RANDOMIZED TRIAL ON THE CLINICAL MANAGEMENT OF ASCUS ANDN01CN055156 · CN · MAGEE-WOMEN'S HOSPITAL OF UPMC · PI GUIDO, RICHARD S. · 1995 to 2000
–
RANDOMIZED TRIAL ON THE CLINICAL MANAGEMENT OF ASCUSN01CN055157 · CN · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI WALKER, JOAN · 1995 to 1999
–
RANDOMIZED TRIAL ON THE CLINICAL MANAGEMENT OFN01CN055105 · CN · UNIVERSITY OF NEW MEXICO · PI WHEELER, COSETTE M · 1995 to 1999
–
RANDOMIZED TRIAL ON THE CLINICAL MANAGEMENT OF ASCUSN01CN055159 · CN · JOHNS HOPKINS UNIVERSITY · PI KURMAN, ROBERT J. · 1995 to 1999
–
NCI NIH HHS N01 CN055105NCI NIH HHS N01 CN055153NCI NIH HHS N01 CN055154NCI NIH HHS N01 CN055155NCI NIH HHS N01 CN055156NCI NIH HHS N01 CN055157NCI NIH HHS N01 CN055158NCI NIH HHS N01 CN055159NCI NIH HHS N01 CP011005NCI NIH HHS P30 CA134274NCI NIH HHS T32 CA009168NHGRI NIH HHS U01 HG011717NHGRI NIH HHS U54 HG006947World Health Organization 001
6 · The paper itself

Abstract

Necessary stages of cervical carcinogenesis include acquisition of a carcinogenic human papillomavirus (HPV) type, persistence associated with the development of precancerous lesions, and invasion. Using prospective data from immunocompetent women in the Guanacaste HPV Natural History Study (NHS), the ASCUS-LSIL Triage Study (ALTS) and the Costa Rica HPV Vaccine Trial (CVT), we compared the early natural history of HPV types to inform transition probabilities for health decision models. We excluded women with evidence of high-grade cervical abnormalities at any point during follow-up and restricted the analysis to incident infections in all women and prevalent infections in young women (aged <30 years). We used survival approaches accounting for interval-censoring to estimate the time to clearance distribution for 20 529 HPV infections (64% were incident and 51% were carcinogenic). Time to clearance was similar across HPV types and risk classes (HPV16, HPV18/45, HPV31/33/35/52/58, HPV 39/51/56/59 and noncarcinogenic HPV types); and by age group (18-29, 30-44 and 45-54 years), among carcinogenic and noncarcinogenic infections. Similar time to clearance across HPV types suggests that relative prevalence can predict relative incidence. We confirmed that there was a uniform linear association between incident and prevalent infections for all HPV types within each study cohort. In the absence of progression to precancer, we observed similar time to clearance for incident infections across HPV types and risk classes. A singular clearance function for incident HPV infections has important implications for the refinement of microsimulation models used to evaluate the cost-effectiveness of novel prevention technologies.

Indexed as

AlphapapillomavirusPapillomavirus InfectionsUterine Cervical DysplasiaUterine Cervical NeoplasmsFemaleHumansPapillomaviridaeProspective Studiesearly natural history of HPVHPV clearanceHPV incidenceHPV prevalence

Identifiers

PMID35603904
PMCPMC9329241
OpenAlexW4281295349

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.